Follow
Roman Gulati
Title
Cited by
Cited by
Year
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ...
New England Journal of Medicine 375 (5), 443-453, 2016
15442016
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context
G Draisma, R Etzioni, A Tsodikov, A Mariotto, E Wever, R Gulati, E Feuer, ...
Journal of the National Cancer Institute 101 (6), 374-383, 2009
9912009
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
A Kumar, I Coleman, C Morrissey, X Zhang, LD True, R Gulati, R Etzioni, ...
Nature medicine 22 (4), 369-378, 2016
6842016
Quantifying the role of PSA screening in the US prostate cancer mortality decline
R Etzioni, A Tsodikov, A Mariotto, A Szabo, S Falcon, J Wegelin, ...
Cancer Causes & Control 19, 175-181, 2008
4962008
Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials
A Tsodikov, R Gulati, EAM Heijnsdijk, PF Pinsky, SM Moss, S Qiu, ...
Annals of internal medicine 167 (7), 449-455, 2017
2552017
Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms
R Gulati, JL Gore, R Etzioni
Annals of internal medicine 158 (3), 145-153, 2013
1982013
Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress
MD Nyquist, A Corella, I Coleman, N De Sarkar, A Kaipainen, G Ha, ...
Cell reports 31 (8), 2020
1712020
Inter-and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
L Brady, M Kriner, I Coleman, C Morrissey, M Roudier, LD True, R Gulati, ...
Nature communications 12 (1), 1426, 2021
1692021
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening
R Etzioni, R Gulati, L Mallinger, J Mandelblatt
Annals of internal medicine 158 (11), 831-838, 2013
1692013
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits
I Lansdorp-Vogelaar, R Gulati, AB Mariotto, CB Schechter, ...
Annals of internal medicine 161 (2), 104-112, 2014
1662014
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines
R Etzioni, R Gulati, A Tsodikov, EM Wever, DF Penson, EAM Heijnsdijk, ...
Cancer 118 (23), 5955-5963, 2012
1622012
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends
D Telesca, R Etzioni, R Gulati
Biometrics 64 (1), 10-19, 2008
1522008
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach
R Etzioni, R Gulati, S Falcon, DF Penson
Medical Decision Making 28 (3), 323-331, 2008
1452008
Is prostate cancer different in black men? Answers from 3 natural history models
A Tsodikov, R Gulati, TM de Carvalho, EAM Heijnsdijk, RA Hunter‐Merrill, ...
Cancer 123 (12), 2312-2319, 2017
1412017
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
MT Schweizer, K Haugk, JS McKiernan, R Gulati, HH Cheng, JL Maes, ...
PloS one 13 (6), e0198389, 2018
1212018
Expected population impacts of discontinued prostate‐specific antigen screening
R Gulati, A Tsodikov, R Etzioni, RA Hunter‐Merrill, JL Gore, AB Mariotto, ...
Cancer 120 (22), 3519-3526, 2014
1162014
Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells
C Morrissey, B Gallis, JW Solazzi, BJ Kim, R Gulati, F Vakar-Lopez, ...
Anti-cancer drugs 21 (4), 423-432, 2010
1162010
Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening
R Etzioni, R Gulati, MR Cooperberg, DM Penson, NS Weiss, ...
Medical care 51 (4), 295-300, 2013
1102013
Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways
L Chéry, HM Lam, I Coleman, B Lakely, R Coleman, S Larson, ...
Oncotarget 5 (20), 9939, 2014
1012014
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ...
Prostate cancer and prostatic diseases 18 (2), 122-127, 2015
992015
The system can't perform the operation now. Try again later.
Articles 1–20